What happened
Lifecore Biomedical, Inc. (NASDAQ: LFCR) said on September 28, 2026, that it entered a definitive agreement to be acquired by Webster Equity Partners.
Common stockholders will receive $6.28 per share in cash at closing, plus one non-tradable CVR per share.
Lifecore also said it signed a three-year extension to its Manufacturing Agreement with Alcon, which runs through 2034.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Cash at closing for common stockholders | $6.28 per share in cash at closing | SEC 8-K Exhibit 99.1 | |
| CVR pool | up to $160 million in the aggregate | SEC 8-K Exhibit 99.1 | |
| Full potential merger consideration | up to $9.67 per share of common stock or common stock equivalent | SEC 8-K Exhibit 99.1 | |
| Transaction value | up to $663.7 million | SEC 8-K Exhibit 99.1 | |
| Cash consideration premium | 49.5% | SEC 8-K Exhibit 99.1 | |
| CVR-inclusive premium | 130.2% | SEC 8-K Exhibit 99.1 |
Why it matters
The CVRs could pay up to $160 million in the aggregate based on performance milestones in 2028, 2029 and 2030. That is about 101% of Lifecore Biomedical, Inc.'s market value, so the CVR piece can matter as much as the cash at closing.
The filing says the $6.28 cash price is a 49.5% premium to Lifecore's closing price on September 25, 2026. If all CVR payments are made, the $9.67 per common equivalent package is a 130.2% premium to that price.
If all milestones are met, stockholders may receive up to $9.67 per common equivalent, compared with $6.28 in cash at closing. The filing says those payments depend on revenue milestones for 2028 and 2029 and an EBITDA milestone for 2030.
That extra value is not assured because the merger still needs stockholder and regulatory approval.
What's next
The transaction is expected to close at the end of the fourth quarter 2026, subject to stockholder approval, required regulatory approvals and other closing conditions.
Lifecore said the merger agreement includes a 30-day go-shop period. During that time, it may solicit, consider and negotiate alternative acquisition proposals from third parties. The board may end the merger agreement to accept a superior proposal, subject to the agreement's terms and conditions.
Lifecore said it will file a definitive proxy statement for a special meeting of stockholders to approve the Merger Agreement and the Merger.
A completed closing would confirm the cash and CVR path described in the filing. If approvals fail, or a better offer emerges during the go-shop, that path would weaken.
Sources
- SEC 8-K Exhibit 99.1 — Press release announcing the definitive merger agreement, cash consideration, CVRs and deal value.
- SEC 8-K Exhibit 99.4 — CEO remarks repeating the merger terms and noting the Alcon extension.
Read the full OptimistFi thesis on Lifecore Biomedical, Inc.: https://optimistfi.com/stocks/LFCR
See what would break the Lifecore Biomedical, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full Lifecore Biomedical, Inc. investment case, its status and the next test to watch live on the Lifecore Biomedical, Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
